Aditxt, Inc. (ADTX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Aditxt, Inc.
Address
737 North Fifth Street
Mountain View, VA 23219
United States of America (the)
Phone
909 488 0844
Website
Sector
Healthcare
Industry
Biotechnology
Employees
26
First IPO Date
June 30, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Amro A. Albanna | Co-Founder, Chairman & Chief Executive Officer | 500,000 | 1970 |
| Jeffrey Busch | Interim Chief Executive Officer | 0 | 1960 |
| Shahrokh Shabahang | Co-Founder, Chief Innovation Officer & Secretary | 325,000 | 1963 |
| Corinne D. Pankovcin | Chief Mergers & Acquisitions Officer | 385,008 | 1966 |
| Thomas J. Farley | Chief Financial Officer | 395,000 | 1974 |
| Rowena Albanna | Chief Operating Officer | 0 | 1966 |
| Christopher J. Porcelli | General Counsel & Chief People Officer | 0 | 1992 |
| Dolly Tyan | Senior Vice President of Clinical Development Transplantation | 0 | N/A |
| Ge Chen | Senior Vice President of Preclinical Research & Discovery | 0 | N/A |
| Jennifer Lee | Director of Human Resources | 0 | N/A |
Description
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.
